Erenumab reduces headache frequency in minor TBI

  • Ashina H & al.
  • J Headache Pain
  • 3 Jun 2020

  • curated by Kelli Whitlock Burton
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients who received erenumab for persistent posttraumatic headache (PTH) following mild traumatic brain injury (TBI) reported fewer moderate-to-severe headache days a month.

Why this matters

  • Despite the prevalence of PTH, no approved pharmacological therapies are available, and research on effective treatments is limited.

Study design

  • 100 patients with a history of persistent headache attributed to mild TBI received 140-mg erenumab injections every 4 weeks for 12 weeks.
  • Funding: Novartis Healthcare A/S.

Key results

  • Headache phenotypes included chronic migraine-like headache (53%), combined episodic migraine-like/tension-type-like headache (TTH; 34%), and ‘pure’ chronic TTH-like headache (13%).
  • 89% were current users of acute headache medication.
  • 74% had used preventive medication, more than half of whom had not gained relief from ≥3 preventive medications.
  • Decrease from baseline in mean number of headache days during study period:
    • Moderate-to-severe intensity: 15.7±9.6 to 2.8±6.8 days/month.
    • Headaches of any severity: 24.6±6.1 to 1.7±6.9 days/month.
  • 28% of patients reported ≥50% reduction in the mean number of headache days, and 47% reported ≥25% decrease.
  • The most common adverse events (AEs) were constipation (n=30) and injection-site reactions (n=15), and no serious AEs were reported.

Limitations

  • Single-center, nonrandomized study.